Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
Season 6, Episode 32, Jun 16, 2024, 11:00 AM
Share
Subscribe
In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
To learn more about the approval of denosumab-bddz, click here.
To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here.
To learn more about the ROSALIA study (NCT05405725), click here.
Extra content: To read more about the Biosimilars Council position paper on how to improve biosimilar development, click here.
To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here.
To learn more about the ROSALIA study (NCT05405725), click here.
Extra content: To read more about the Biosimilars Council position paper on how to improve biosimilar development, click here.